MétaCan
Menu
Retour à la cohorte
Enregistrement W4210689349 · doi:10.1001/jamaoncol.2021.6744

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

2022· article· en· W4210689349 sur OpenAlexafffund
Nasim Mavaddat, Leila Dorling, Sara Carvalho, Jamie Allen, Anna González‐Neira, Renske Keeman, Manjeet K. Bolla, Joe Dennis, Qin Wang, Thomas U. Ahearn, Irene L. Andrulis, Matthias W. Beckmann, Sabine Behrens, Javier Benı́tez, Marina Bermisheva, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Ignacio Briceño, Thomas Brüning, Nicola J. Camp, Archie Campbell, Jose E. Castelao, Jenny Chang‐Claude, Stephen J. Chanock, Georgia Chenevix‐Trench, Hans Christiansen, Kamila Czene, Thilo Dörk, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine D. Figueroa, Henrik Flyger, Marike Gabrielson, Manuela Gago-Domínguez, Jürgen Geisler, Graham G. Giles, Pascal Guénel, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Jaana M. Hartikainen, Mikael Hartman, Reiner Hoppe, Anna Jakubowska, Audrey Jung, Э. К. Хуснутдинова, Vessela N. Kristensen, Jingmei Li, Swee Ho Lim, Annika Lindblom, Maria A. Loizidou, Artitaya Lophatananon, Jan Lubiński, Michael J. Madsen, Mehdi Manoochehri, Sara Margolin, Dimitrios Mavroudis, Roger L. Milne, Nur Aishah Mohd Taib, Anna Morra, Kenneth Muir, Nadia Obi, Ana Osório, Tjoung‐Won Park‐Simon, Paolo Peterlongo, Paolo Radice, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Mitul Shah, Xueling Sim, Melissa C. Southey, Heather Thorne, Ian Tomlinson, Diana Torres, Thérèse Truong, Cheng Har Yip, Amanda B. Spurdle, Maaike P.G. Vreeswijk, Alison M. Dunning, Montserrat García‐Closas, Paul D.P. Pharoah, Anders Kvist, Taru Muranen, Heli Nevanlinna, Soo‐Hwang Teo, Peter Devilee, Marjanka K. Schmidt, Douglas F. Easton

Notice bibliographique

RevueJAMA Oncology · 2022
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueBRCA gene mutations in cancer
Établissements canadiensLunenfeld-Tanenbaum Research InstituteUniversity of TorontoMount Sinai Hospital
Organismes subventionnairesMedical Research and Materiel CommandDavid Geffen School of Medicine, University of California, Los AngelesEuropean Regional Development FundNational Cancer InstituteMedisinske fakultet, Universitetet i OsloServicio Gallego de SaludUniversitätsklinikum Hamburg-EppendorfScottish GovernmentKWF KankerbestrijdingDet Sundhedsvidenskabelige Fakultet, Københavns UniversitetInstituto de Salud Carlos IIIFreistaat SachsenRussian Academy of SciencesMedical Research CouncilEuropean CommissionCanadian Institutes of Health ResearchDirectorate for Biological SciencesNational Institutes of HealthUniversité de Versailles Saint-Quentin-en-YvelinesUniversitätsklinikum KölnAkershus UniversitetssykehusNational University Health SystemAgency for Science, Technology and ResearchUniversidad de La SabanaPomorski Uniwersytet Medyczny W SzczecinieInstitut Gustave-RoussyUniversität zu KölnFondazione Italiana per la Ricerca sul CancroMedizinischen Hochschule HannoverKreftforeningenInstitut National Du CancerLeids Universitair Medisch CentrumKarolinska InstitutetAssociazione Italiana per la Ricerca sul CancroDeutsche KrebshilfeNational Health and Medical Research CouncilUniversiti MalayaNorges ForskningsrådNational Medical Research CouncilStockholms Läns LandstingSundhed og Sygdom, Det Frie ForskningsrådSaint Petersburg State UniversityKuopion Yliopistollinen SairaalaUniversity of TorontoPontificia Universidad JaverianaKing's College LondonGentofte HospitalDeutsche ForschungsgemeinschaftDeutsche Gesetzliche UnfallversicherungAlexander von Humboldt-StiftungCancerfondenCancer Council VictoriaUniversity of MelbourneRobert Bosch StiftungProgramme Grants for Applied ResearchManchester Biomedical Research CentreMonash UniversityItä-Suomen YliopistoEberhard Karls Universität TübingenUniversiteit LeidenCancer Research InstituteUniversity of CreteInstitut National de la Santé et de la Recherche MédicaleInstitute of GeneticsWellcome TrustAgence Nationale de la RechercheLunds UniversitetFaculty of Health and Medical Sciences, University of Western AustraliaCancer Research UKNational University of SingaporeNational Research Foundation SingaporeNational Institute for Health and Care ResearchNIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer ResearchNational Research FoundationChief Scientist Office, Scottish Government Health and Social Care DirectorateBundesministerium für Bildung und ForschungGenome Institute of SingaporeNational Breast Cancer FoundationQIMR Berghofer Medical Research InstituteResearch Promotion FoundationEngineering and Physical Sciences Research CouncilFondation de FranceUniversity of CambridgeGovernment of CanadaBreast Cancer Research TrustFondation du cancer du sein du QuébecDuke-NUS Medical SchoolHuntsman Cancer InstituteScottish Funding CouncilInstituto de Investigación Sanitaria de Santiago de CompostelaDeutsches KrebsforschungszentrumHelsingin YliopistoGenome CanadaUniversity of California, San DiegoUniversitetet i OsloUniversity of OxfordCancer Council NSWSusan G. Komen for the Cure
Mots-clésMedicineGermlineBreast cancerGeneGermline mutationCancerPathologyOncologyGeneticsInternal medicineMutationBiology

Résumé

récupéré en direct d'OpenAlex

IMPORTANCE: Rare germline genetic variants in several genes are associated with increased breast cancer (BC) risk, but their precise contributions to different disease subtypes are unclear. This information is relevant to guidelines for gene panel testing and risk prediction. OBJECTIVE: To characterize tumors associated with BC susceptibility genes in large-scale population- or hospital-based studies. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, international case-control analysis of the BRIDGES study included 42 680 patients and 46 387 control participants, comprising women aged 18 to 79 years who were sampled independently of family history from 38 studies. Studies were conducted between 1991 and 2016. Sequencing and analysis took place between 2016 and 2021. EXPOSURES: Protein-truncating variants and likely pathogenic missense variants in ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53. MAIN OUTCOMES AND MEASURES: The intrinsic-like BC subtypes as defined by estrogen receptor, progesterone receptor, and ERBB2 (formerly known as HER2) status, and tumor grade; morphology; size; stage; lymph node involvement; subtype-specific odds ratios (ORs) for carrying protein-truncating variants and pathogenic missense variants in the 9 BC susceptibility genes. RESULTS: The mean (SD) ages at interview (control participants) and diagnosis (cases) were 55.1 (11.9) and 55.8 (10.6) years, respectively; all participants were of European or East Asian ethnicity. There was substantial heterogeneity in the distribution of intrinsic subtypes by gene. RAD51C, RAD51D, and BARD1 variants were associated mainly with triple-negative disease (OR, 6.19 [95% CI, 3.17-12.12]; OR, 6.19 [95% CI, 2.99-12.79]; and OR, 10.05 [95% CI, 5.27-19.19], respectively). CHEK2 variants were associated with all subtypes (with ORs ranging from 2.21-3.17) except for triple-negative disease. For ATM variants, the association was strongest for the hormone receptor (HR)+ERBB2- high-grade subtype (OR, 4.99; 95% CI, 3.68-6.76). BRCA1 was associated with increased risk of all subtypes, but the ORs varied widely, being highest for triple-negative disease (OR, 55.32; 95% CI, 40.51-75.55). BRCA2 and PALB2 variants were also associated with triple-negative disease. TP53 variants were most strongly associated with HR+ERBB2+ and HR-ERBB2+ subtypes. Tumors occurring in pathogenic variant carriers were of higher grade. For most genes and subtypes, a decline in ORs was observed with increasing age. Together, the 9 genes were associated with 27.3% of all triple-negative tumors in women 40 years or younger. CONCLUSIONS AND RELEVANCE: The results of this case-control study suggest that variants in the 9 BC risk genes differ substantially in their associated pathology but are generally associated with triple-negative and/or high-grade disease. Knowing the age and tumor subtype distributions associated with individual BC genes can potentially aid guidelines for gene panel testing, risk prediction, and variant classification and guide targeted screening strategies.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,001
score de la tête « metaresearch » (Gemma)0,001
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,002
Score d'incertitude au seuil0,006

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0010,001
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0020,001
Études des sciences et des technologies0,0000,000
Communication savante0,0010,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0020,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,011
Tête enseignante GPT0,281
Écart entre enseignants0,270 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations190
Publié2022
Routes d'admission2
Résumé présentoui

Explorer davantage

Même revueJAMA OncologyMême sujetBRCA gene mutations in cancerTravaux en français237 207